overview
Novocure® is developing TTFields for different cancer diseases. This website is designed to assist patients, their family members, and caregivers in accessing clinical study sites for potential participation in ongoing studies.
TTFields are electric fields that disrupt cancer cell division. TTFields are delivered to the region of the cancer using a lightweight, battery-operated medical device. The device applies TTFields non-invasively, and gives patients the option to maintain their lifestyle while receiving TTFields treatment.
The use of TTFields has been approved by the FDA via the Premarket Approval Pathway for the treatment of GBM, together with temozolomide. TTFields therapy has obtained a CE mark in Europe, and is approved in Japan for the same indication. TTFields are experimental for all indications mentioned in these clinical studies and has not been approved for their treatment.
clinical trials
METIS
Brain metastasis
The METIS study is intended for patients diagnosed with brain metastases from non-small-cell lung cancer.
learn moreLUNAR
Lung cancer
The LUNAR study is intended for patients diagnosed with advanced non-small cell lung cancer (NSCLC).
learn moreENGOT-ov50 / INNOVATE-3
Ovarian cancer
The ENGOT-0v50/INNOVATE-3 study is intended for patients diagnosed with platinum resistant, recurrent ovarian cancer.
learn moreTRIDENT
Glioblastoma
The TRIDENT study is intended for patients recently diagnosed with glioblastoma multiforme (GBM).
learn moreZL-8301-001
Gastric cancer
The ZL-8301-001 study is intended for patients diagnosed with gastric cancer (Gastroesophageal Junction (GEJ) Adenocarcinoma, or Gastric (GC) Adenocarcinoma) that cannot be treated with surgery.
learn morePANOVA-3
Pancreatic cancer
The PANOVA-3 study is intended for patients with newly-diagnosed pancreatic cancer that cannot be treated with surgery.
learn moreEF-33
Glioblastoma
The EF-33 study is intended for patients recently diagnosed with recurrent glioblastoma.
learn moreKEYNOTE B36
Lung cancer
The KEYNOTE B36 study is intended for patients who have been diagnosed with, but have not yet been treated for, advanced or metastatic intrathoracic non-small cell lung cancer (NSCLC).
learn morefind a trial
Enter your details below to help us find a trial match for you.